Korean J Urol.  2011 Feb;52(2):79-89.

Metabolomics: A Novel Approach to Early and Noninvasive Prostate Cancer Detection

• Roberts MJ
• Schirra HJ
• Lavin MF
• Gardiner R

Abstract

Prostate cancer (PCa) is the most commonly diagnosed visceral cancer in men and is responsible for the second highest cancer-related male mortality rate in Western countries, with increasing rates being reported in Korea, Japan, and China. Considering the low sensitivity of prostate-specific antigen (PSA) testing, it is widely agreed that reliable, age-independent markers of the presence, nature, and progression of PCa are required to facilitate diagnosis and timely treatment. Metabolomics or metabonomics has recently emerged as a novel method of PCa detection owing to its ability to monitor changes in the metabolic signature, within biofluids or tissue, that reflect changes in phenotype and function. This review outlines the physiology of prostate tissue and prostatic fluid in health and in malignancy in relation to metabolomics as well as the principles underlying the methods of metabolomic quantification. Promising metabolites, metabolic profiles, and their correlation with the presence and stage of PCa are summarized. Application of metabolomics to biofluids and in vivo quantification as well as the direction of current research in supplementing and improving current methods of detection are discussed. The current debate in the urology literature on sarcosine as a potential biomarker for PCa is reviewed and discussed. Metabolomics promises to be a valuable tool in the early detection of PCa that may enable earlier treatment and improved clinical outcomes.

Keyword

Biological markers; Detection; Metabolomics; Prostatic neoplasms

MeSH Terms

Biomarkers
China
Humans
Japan
Korea
Male
Metabolome
Metabolomics
Organothiophosphorus Compounds
Passive Cutaneous Anaphylaxis
Phenotype
Prostate
Prostate-Specific Antigen
Prostatic Neoplasms
Sarcosine
Urology
Organothiophosphorus Compounds
Prostate-Specific Antigen
Sarcosine

Figure

• 

  FIG. 1 Summary of targets in the 'omic' era of analysis. The hierarchical levels of cellular organization involved in the progression from genotype to phenotype are shown. This expression of cellular phenotype is tightly regulated by feedback mechanisms, as shown above the progression. Through this process, various targets are available for analysis and opportunistic manipulation, as shown below the progression.

• 

  FIG. 2 Summary of peripheral prostate physiology in health (left) and disease (right). Healthy peripheral prostate physiology involves citrate accumulation via the zinc-dependent inhibition of m-aconitase, resulting in reduced ATP production via the Krebs cycle and a greater dependence on glucose and aspartate for ATP. In malignancy, peripheral prostate cells lose their ability to accumulate zinc, resulting in isomerization of citrate via m-aconitase for metabolism in the Krebs cycle and reduced citrate accumulation and production.

• 

  FIG. 3 Relationships between different quantification methods. The relationships between different quantification methods are shown. The basic techniques of quantification are listed on the left side, their relationships and combinations are shown in the middle of the diagram, and the result of these relationships is shown on the right side. These are the principal methods of quantification in prostate cancer (PCa) metabolomics. LC-MS: liquid chromatography mass spectrometry, GC-MS: gas chromatography mass spectrometry, NMR: nuclear magnetic resonance, MRI: magnetic resonance imaging, MRSI: magnetic resonance spectroscopic imaging, PET: positron emission tomography.

Reference

1. Park SK, Sakoda LC, Kang D, Chokkalingam AP, Lee E, Shin HR, et al. Rising prostate cancer rates in South Korea. Prostate. 2006. 66:1285–1291.

2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010. 60:277–300.

3. Marugame T, Mizuno S. Comparison of prostate cancer mortality in five countries: France, Italy, Japan, UK and USA from the WHO mortality database (1960-2000). Jpn J Clin Oncol. 2005. 35:690–691.

4. Sim HG, Cheng CW. Changing demography of prostate cancer in Asia. Eur J Cancer. 2005. 41:834–845.

5. Yang S Y, Adelstein J, Kassis AI. Putative molecular signatures for the imaging of prostate cancer. Expert Rev Mol Diagn. 2010. 10:65–74.

6. Narain V, Cher ML, Wood DP Jr. Prostate cancer diagnosis, staging and survival. Cancer Metastasis Rev. 2002. 21:17–27.

7. Lin K, Lipsitz R, Miller T, Janakiraman S. Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force. Ann Intern Med. 2008. 149:192–199.

8. Crawford ED. PSA testing: what is the use? Lancet. 2005. 365:1447–1449.

9. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med. 2004. 350:2239–2246.

10. Pienta KJ. Critical appraisal of prostate-specific antigen in prostate cancer screening: 20 years later. Urology. 2009. 73:5 Suppl. S11–S20.

11. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009. 360:1320–1328.

12. Barry MJ. Screening for prostate cancer--the controversy that refuses to die. N Engl J Med. 2009. 360:1351–1354.

13. Bensalah K, Lotan Y, Karam JA, Shariat SF. New circulating biomarkers for prostate cancer. Prostate Cancer Prostatic Dis. 2008. 11:112–120.

14. Veltri RW, Miller MC, O'dowd GJ, Partin AW. Impact of age on total and complexed prostate-specific antigen cutoffs in a contemporary referral series of men with prostate cancer. Urology. 2002. 60:4 Suppl 1. 47–52.

15. Fitzpatrick JM. The natural history of benign prostatic hyperplasia. BJU Int. 2006. 97:Suppl 2. 3–6.

16. Stenman UH, Leinonen J, Zhang WM, Finne P. Prostate-specific antigen. Semin Cancer Biol. 1999. 9:83–93.

17. Hansel DE, DeMarzo AM, Platz EA, Jadallah S, Hicks J, Epstein JI, et al. Early prostate cancer antigen expression in predicting presence of prostate cancer in men with histologically negative biopsies. J Urol. 2007. 177:1736–1740.

18. Serkova NJ, Gamito EJ, Jones RH, O'Donnell C, Brown JL, Green S, et al. The metabolites citrate, myo-inositol, and spermine are potential age-independent markers of prostate cancer in human expressed prostatic secretions. Prostate. 2008. 68:620–628.

19. DeFeo EM, Cheng LL. Characterizing human cancer metabolomics with ex vivo 1H HRMAS MRS. Technol Cancer Res Treat. 2010. 9:381–391.

20. Hricak H, Choyke PL, Eberhardt SC, Leibel SA, Scardino PT. Imaging prostate cancer: a multidisciplinary perspective. Radiology. 2007. 243:28–53.

21. Clarke RA, Schirra HJ, Catto JW, Lavin MF, Gardiner RA. Markers for detection of prostate cancer. Cancers. 2010. 2:1125–1154.

22. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009. 457:910–914.

23. Nicholson JK, Lindon JC, Holmes E. 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica. 1999. 29:1181–1189.

24. Costello LC, Franklin RB. The clinical relevance of the metabolism of prostate cancer; zinc and tumor suppression: connecting the dots. Mol Cancer. 2006. 5:17.

25. Griffin JL, Shockcor JP. Metabolic profiles of cancer cells. Nat Rev Cancer. 2004. 4:551–561.

26. Abate-Shen C, Shen MM. Diagnostics: the prostate-cancer metabolome. Nature. 2009. 457:799–800.

27. Spratlin JL, Serkova NJ, Eckhardt SG. Clinical applications of metabolomics in oncology: a review. Clin Cancer Res. 2009. 15:431–440.

28. Serkova NJ, Spratlin JL, Eckhardt SG. NMR-based metabolomics: translational application and treatment of cancer. Curr Opin Mol Ther. 2007. 9:572–585.

29. Costello LC, Franklin RB. Prostatic fluid electrolyte composition for the screening of prostate cancer: a potential solution to a major problem. Prostate Cancer Prostatic Dis. 2009. 12:17–24.

30. Teahan O, Bevan CL, Waxman J, Keun HC. Metabolic signatures of malignant progression in prostate epithelial cells. Int J Biochem Cell Biol. 2010. Epub ahead of print.

31. Lynch MJ, Masters J, Pryor JP, Lindon JC, Spraul M, Foxall PJ, et al. Ultra high field NMR spectroscopic studies on human seminal fluid, seminal vesicle and prostatic secretions. J Pharm Biomed Anal. 1994. 12:5–19.

32. Liney GP, Turnbull LW, Lowry M, Turnbull LS, Knowles AJ, Horsman A. In vivo quantification of citrate concentration and water T2 relaxation time of the pathologic prostate gland using 1H MRS and MRI. Magn Reson Imaging. 1997. 15:1177–1186.

33. Warburg O. On the origin of cancer cells. Science. 1956. 123:309–314.

34. Dakubo GD, Parr RL, Costello LC, Franklin RB, Thayer RE. Altered metabolism and mitochondrial genome in prostate cancer. J Clin Pathol. 2006. 59:10–16.

35. Sciarra A, Panebianco V, Ciccariello M, Salciccia S, Lisi D, Osimani M, et al. Magnetic resonance spectroscopic imaging (1H-MRSI) and dynamic contrast-enhanced magnetic resonance (DCE-MRI): pattern changes from inflammation to prostate cancer. Cancer Invest. 2010. 28:424–432.

36. Noworolski SM, Vigneron DB, Chen AP, Kurhanewicz J. Dynamic contrast-enhanced MRI and MR diffusion imaging to distinguish between glandular and stromal prostatic tissues. Magn Reson Imaging. 2008. 26:1071–1080.

37. Cheng LL, Burns MA, Taylor JL, He W, Halpern EF, McDougal WS, et al. Metabolic characterization of human prostate cancer with tissue magnetic resonance spectroscopy. Cancer Res. 2005. 65:3030–3034.

38. Serkova NJ, Freund AS, Brown JL, Kominsky DJ. Use of the 1-mm micro-probe for metabolic analysis on small volume biological samples. J Cell Mol Med. 2009. 13:1933–1941.

39. Costello LC, Franklin RB, Narayan P. Citrate in the diagnosis of prostate cancer. Prostate. 1999. 38:237–245.

40. Glunde K, Serkova NJ. Therapeutic targets and biomarkers identified in cancer choline phospholipid metabolism. Pharmacogenomics. 2006. 7:1109–1123.

41. Lynch MJ, Nicholson JK. Proton MRS of human prostatic fluid: correlations between citrate, spermine, and myo-inositol levels and changes with disease. Prostate. 1997. 30:248–255.

42. Cooper JF, Imfeld H. The role of citric acid in the physiology of the prostate: a preliminary report. J Urol. 1959. 81:157–164.

43. Averna TA, Kline EE, Smith AY, Sillerud LO. A decrease in 1H nuclear magnetic resonance spectroscopically determined citrate in human seminal fluid accompanies the development of prostate adenocarcinoma. J Urol. 2005. 173:433–438.

44. Kline EE, Treat EG, Averna TA, Davis MS, Smith AY, Sillerud LO. Citrate concentrations in human seminal fluid and expressed prostatic fluid determined via 1H nuclear magnetic resonance spectroscopy outperform prostate specific antigen in prostate cancer detection. J Urol. 2006. 176:2274–2279.

45. Zaichick VY, Sviridova TV, Zaichick SV. Zinc concentration in human prostatic fluid: normal, chronic prostatitis, adenoma and cancer. Int Urol Nephrol. 1996. 28:687–694.

46. Cooper JF, Farid I. The role of citric acid in the physiology of the prostate. 3. lactate/citrate ratios in benign and malignant prostatic homogenates as an index of prostatic malignancy. J Urol. 1964. 92:533–536.

47. Kurhanewicz J, Dahiya R, Macdonald JM, Chang LH, James TL, Narayan P. Citrate alterations in primary and metastatic human prostatic adenocarcinomas: 1H magnetic resonance spectroscopy and biochemical study. Magn Reson Med. 1993. 29:149–157.

48. Cornel EB, Smits GA, Oosterhof GO, Karthaus HF, Deburyne FM, Schalken JA, et al. Characterization of human prostate cancer, benign prostatic hyperplasia and normal prostate by in vitro 1H and 31P magnetic resonance spectroscopy. J Urol. 1993. 150:2019–2024.

49. Mintz A, Wang L, Ponde DE. Comparison of radiolabeled choline and ethanolamine as probe for cancer detection. Cancer Biol Ther. 2008. 7:742–747.

50. Podo F. Tumour phospholipid metabolism. NMR Biomed. 1999. 12:413–439.

51. van Asten JJ, Cuijpers V, Hulsbergen-van de Kaa C, Soede-Huijbregts C, Witjes JA, Verhofstad A, et al. High resolution magic angle spinning NMR spectroscopy for metabolic assessment of cancer presence and Gleason score in human prostate needle biopsies. MAGMA. 2008. 21:435–442.

52. Tessem MB, Swanson MG, Keshari KR, Albers MJ, Joun D, Tabatabai ZL, et al. Evaluation of lactate and alanine as metabolic biomarkers of prostate cancer using 1H HR-MAS spectroscopy of biopsy tissues. Magn Reson Med. 2008. 60:510–516.

53. Mori R, Dorff TB, Xiong S, Tarabolous CJ, Ye W, Groshen S, et al. The relationship between proangiogenic gene expression levels in prostate cancer and their prognostic value for clinical outcomes. Prostate. 2010. 70:1692–1700.

54. Stenman K, Hauksson JB, Gröbner G, Stattin P, Bergh A, Riklund K. Detection of polyunsaturated omega-6 fatty acid in human malignant prostate tissue by 1D and 2D high-resolution magic angle spinning NMR spectroscopy. MAGMA. 2009. 22:327–331.

55. Swanson MG, Zektzer AS, Tabatabai ZL, Simko J, Jarso S, Keshari KR, et al. Quantitative analysis of prostate metabolites using 1H HR-MAS spectroscopy. Magn Reson Med. 2006. 55:1257–1264.

56. Kurhanewicz J, Vigneron DB, Nelson SJ. Three-dimensional magnetic resonance spectroscopic imaging of brain and prostate cancer. Neoplasia. 2000. 2:166–189.

57. Swanson MG, Vigneron DB, Tabatabai ZL, Males RG, Schmitt L, Carroll PR, et al. Proton HR-MAS spectroscopy and quantitative pathologic analysis of MRI/3D-MRSI-targeted postsurgical prostate tissues. Magn Reson Med. 2003. 50:944–954.

58. Schilling D, Schlemmer HP, Wagner PH, Bottcher P, Merseburger AS, Aschoff P, et al. Histological verification of 11C-choline-positron emission/computed tomography-positive lymph nodes in patients with biochemical failure after treatment for localized prostate cancer. BJU Int. 2008. 102:446–451.

59. Mazaheri Y, Shukla-Dave A, Hricak H, Fine SW, Zhang J, Inurrigarro G, et al. Prostate cancer: identification with combined diffusion-weighted MR imaging and 3D 1H MR spectroscopic imaging--correlation with pathologic findings. Radiology. 2008. 246:480–488.

60. Scheenen TW, Heijmink SW, Roell SA, Hulsbergen-Van de Kaa CA, Knipscheer BC, Witjes JA, et al. Three-dimensional proton MR spectroscopy of human prostate at 3 T without endorectal coil: feasibility. Radiology. 2007. 245:507–516.

61. Swanson MG, Keshari KR, Tabatabai ZL, Simko JP, Shinohara K, Carroll PR, et al. Quantification of choline- and ethanolamine-containing metabolites in human prostate tissues using 1H HR-MAS total correlation spectroscopy. Magn Reson Med. 2008. 60:33–40.

62. Wu CL, Jordan KW, Ratai EM, Sheng J, Adkins CB, Defeo EM, et al. Metabolomic imaging for human prostate cancer detection. Sci Transl Med. 2010. 2:16ra8.

63. Maxeiner A, Adkins CB, Zhang Y, Taupitz M, Halpern EF, McDougal WS, et al. Retrospective analysis of prostate cancer recurrence potential with tissue metabolomic profiles. Prostate. 2010. 70:710–717.

64. Kavanagh JP, Darby C, Costello CB. The response of seven prostatic fluid components to prostatic disease. Int J Androl. 1982. 5:487–496.

65. Menard C, Smith IC, Somorjai RL, Leboldus L, Patel R, Littman C, et al. Magnetic resonance spectroscopy of the malignant prostate gland after radiotherapy: a histopathologic study of diagnostic validity. Int J Radiat Oncol Biol Phys. 2001. 50:317–323.

66. Mueller-Lisse UG, Swanson MG, Vigneron DB, Hricak H, Bessette A, Males RG, et al. Time-dependent effects of hormone-deprivation therapy on prostate metabolism as detected by combined magnetic resonance imaging and 3D magnetic resonance spectroscopic imaging. Magn Reson Med. 2001. 46:49–57.

67. Fass L. Imaging and cancer: a review. Mol Oncol. 2008. 2:115–152.

68. Kurhanewicz J, Vigneron DB. Advances in MR spectroscopy of the prostate. Magn Reson Imaging Clin N Am. 2008. 16:697–710.

69. Hom JJ, Coakley FV, Simko JP, Lu Y, Qayyum A, Westphalen AC, et al. High-grade prostatic intraepithelial neoplasia in patients with prostate cancer: MR and MR spectroscopic imaging features--initial experience. Radiology. 2007. 242:483–489.

70. Takyi EE, Fuller DJ, Donaldson LJ, Thomas GH. Deoxyribonucleic acid and polyamine synthesis in rat ventral prostrate. Effects of age of the intact rat and androgen stimulation of the castrated rat with testosterone, 5 alpha-dihydrotestosterone and 5 alpha-androstane-3 beta, 17 beta-diol. Biochem J. 1977. 162:87–97.

71. Kurhanewicz J, Swanson MG, Nelson SJ, Vigneron DB. Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer. J Magn Reson Imaging. 2002. 16:451–463.

72. Scheidler J, Hricak H, Vigneron DB, Yu KK, Sokolov DL, Huang LR, et al. Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging--clinicopathologic study. Radiology. 1999. 213:473–480.

73. Yu KK, Scheidler J, Hricak H, Vigneron DB, Zaloudek CJ, Males RG, et al. Prostate cancer: prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. Radiology. 1999. 213:481–488.

74. Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med. 1998. 39:990–995.

75. Krause BJ, Souvatzoglou M, Tuncel M, Herrmann K, Buck AK, Praus C, et al. The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging. 2008. 35:18–23.

76. Price DT, Coleman RE, Liao RP, Robertson CN, Polascik TJ, DeGrado TR. Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol. 2002. 168:273–280.

77. Kirikae M, Diksic M, Yamamoto YL. Quantitative measurements of regional glucose utilization and rate of valine incorporation into proteins by double-tracer autoradiography in the rat brain tumor model. J Cereb Blood Flow Metab. 1989. 9:87–95.

78. Ishiwata K, Kubota K, Murakami M, Kubota R, Senda M. A comparative study on protein incorporation of L-[methyl-3H]methionine, L-[1-14C]leucine and L-2-[18F]fluorotyrosine in tumor bearing mice. Nucl Med Biol. 1993. 20:895–899.

79. Anderson RU, Fair WR. Physical and chemical determinations of prostatic secretion in benign hyperplasia, prostatitis, and adenocarcinoma. Invest Urol. 1976. 14:137–140.

80. van der Graaf M, Schipper RG, Oosterhof GO, Schalken JA, Verhofstad AA, Heerschap A. Proton MR spectroscopy of prostatic tissue focused on the detection of spermine, a possible biomarker of malignant behavior in prostate cancer. MAGMA. 2000. 10:153–159.

81. García-Segura JM, Sánchez-Chapado M, Ibarburen C, Viaño J, Angulo JC, González J, et al. In vivo proton magnetic resonance spectroscopy of diseased prostate: spectroscopic features of malignant versus benign pathology. Magn Reson Imaging. 1999. 17:755–765.

82. Struys EA, Heijboer AC, van Moorselaar J, Jakobs C, Blankenstein MA. Serum sarcosine is not a marker for prostate cancer. Ann Clin Biochem. 2010. 47:282.

83. Schalken JA. Is urinary sarcosine useful to identify patients with significant prostate cancer? The trials and tribulations of biomarker development. Eur Urol. 2010. 58:19–20.

84. Stephan C, Jentzmik F, Jung K. Reply from Authors re: Jack A. Schalken. Is urinary sarcosine useful to identify patients with significant prostate cancer? The trials and tribulations of biomarker development. Eur Urol 2010;58:19-20. Eur Urol. 2010. 58:20–21.

85. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, et al. Re: Florian Jentzmik, Carsten Stephan, Kurt Miller, et al. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. Eur Urol 2010;58:12-8. Eur Urol. 2010. 58:e29–e30.

86. Jentzmik F, Stephan C, Jung K. Reply to Arun Sreekumar, Laila M. Poisson, Thekkelnaycke M. Rajendiran, et al.'s Letter to the Editor re: Florian Jentzmik, Carsten Stephan, Kurt Miller, et al. Sarcosine in Urine after Digital Rectal Examination Fails as a Marker in Prostate Cancer Detection and Identification of Aggressive Tumours. Eur Urol 2010;58:12-8. Eur Urol. 2010. 58:e31–e32.

87. Hewavitharana AK. Re: Florian Jentzmik, Carsten Stephan, Kurt Miller, et al. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. Eur Urol 2010;58:12-8. Eur Urol. 2010. 58:e39–e40.

88. Jentzmik F, Stephan C, Jung K. Reply to Amitha K Hewavitharana's Letter to the Editor re: Florian Jentzmik, Carsten Stephan, Kurt Miller, et al. Sarcosine in Urine After Digital Examination Fails as a Marker in Prostate Cancer Detection and Identification of Aggressive Tumours. Eur Urol 2010;58:12-8. Eur Urol. 2010. 58:e41–e42.

89. Colleselli D, Stenzl A, Schwentner C. Re: Florian Jentzmik, Carsten Stephan, Kurt Miller, et al. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. Eur Urol 2010; 58:12-8. Eur Urol. 2010. 58:e51.

90. Jentzmik F, Stephan C, Miller K, Schrader M, Erbersdobler A, Kristiansen G, et al. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. Eur Urol. 2010. 58:12–18.

91. Jentzmik F, Stephan C, Lein M, Miller K, Kamlage B, Bethan B, et al. Sarcosine in prostate cancer tissue is not a differential metabolite for prostate cancer aggressiveness and biochemical progression. J Urol. 2010. Epub ahead of print.

92. Burns MA, He W, Wu CL, Cheng LL. Quantitative pathology in tissue MR spectroscopy based human prostate metabolomics. Technol Cancer Res Treat. 2004. 3:591–598.

93. Mahdy AE, Cheng JC, Li J, Elojeimy S, Meacham WD, Turner LS, et al. Acid ceramidase upregulation in prostate cancer cells confers resistance to radiation: AC inhibition, a potential radiosensitizer. Mol Ther. 2009. 17:430–438.

94. Umbehr M, Bachmann LM, Held U, Kessler TM, Sulser T, Weishaupt D, et al. Combined magnetic resonance imaging and magnetic resonance spectroscopy imaging in the diagnosis of prostate cancer: a systematic review and meta-analysis. Eur Urol. 2009. 55:575–590.

95. Cheng LL, Wu C, Smith MR, Gonzalez RG. Non-destructive quantitation of spermine in human prostate tissue samples using HRMAS 1H NMR spectroscopy at 9.4 T. FEBS Lett. 2001. 494:112–116.

96. Jadvar H. Molecular imaging of prostate cancer: a concise synopsis. Mol Imaging. 2009. 8:56–64.

97. Kurhanewicz J, Vigneron DB, Nelson SJ, Hricak H, MacDonald JM, Konety B, et al. Citrate as an in vivo marker to discriminate prostate cancer from benign prostatic hyperplasia and normal prostate peripheral zone: detection via localized proton spectroscopy. Urology. 1995. 45:459–466.

98. Heerschap A, Jager GJ, van der Graaf M, Barentsz JO, de la Rosette JJ, Oosterhof GO, et al. In vivo proton MR spectroscopy reveals altered metabolite content in malignant prostate tissue. Anticancer Res. 1997. 17:1455–1460.

99. Kumar R, Nayyar R, Kumar V, Gupta NP, Hemal AK, Jagannathan NR, et al. Potential of magnetic resonance spectroscopic imaging in predicting absence of prostate cancer in men with serum prostate-specific antigen between 4 and 10 ng/ml: a follow-up study. Urology. 2008. 72:859–863.

100. Kurhanewicz J, Vigneron DB, Hricak H, Narayan P, Carroll P, Nelson SJ. Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution. Radiology. 1996. 198:795–805.